Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA6 | P23280 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19051220 | 0.92 | CA1 (0.41) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL3165178 | 0.83 | GRM2 (0.50) | CA1CA2CA9CA12LMNA | |
| SCHEMBL17318441 | 0.83 | CA1 (0.49) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL19051228 | 0.78 | CA1 (0.46) | CA1CA2CA9CA12KDM4E | |
| SCHEMBL17318400 | 0.78 | SCN9A (0.46) | ALDH1A1KMT2A | |
| SCHEMBL17318470 | 0.78 | MMP13 (0.47) | ALDH1A1TSHRKMT2A | |
| SCHEMBL17318395 | 0.75 | MMP13 (0.47) | ALDH1A1KMT2A | |
| SCHEMBL17326791 | 0.75 | SMN1; SMN2 (0.46) | ALDH1A1KMT2A | |
| SCHEMBL17326790 | 0.75 | SMN1; SMN2 (0.46) | ALDH1A1KMT2A | |
| SCHEMBL17318401 | 0.75 | SMN1; SMN2 (0.46) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407382-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407382-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3152188-B1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3152188-B1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-9926262-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926262-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| EP-3152188-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015188152-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015188152-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407382-B2 | EP4 agonists as therapeutic compounds | PTGER4, PTGER1, PTGER3 | CA1 4548/4885CA2 4606/4885CA9 4848/4885 |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | PTGER4, PTGER1, PTGER3 | CA1 4605/4885CA2 4666/4885CA9 4867/4885 |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | PTGER4, PTGER1, PTGER3 | CA1 4605/4885CA2 4666/4885CA9 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.